Pain is common among opioid-dependent patients, yet pharmacologic strategies are limited. The aim of this study was to explore whether escitalopram, a selective serotonin reuptake inhibitor, was associated with reductions in pain. The study used longitudinal data from a randomized, controlled trial that evaluated the effects of escitalopram on treatment retention in patients with depressive symptoms who were initiating buprenorphine/naloxone for treatment of opioid dependence. Participants were randomized to receive escitalopram 10 mg or placebo daily. Changes in pain severity, pain interference, and depression were assessed at 1-, 2-, and 3-month visits with the visual analog scale, Brief Pain Inventory, and the Beck Depression Inventory II, respectively. Fixed-effects estimators for panel regression models were used to assess the effects of intervention on changes in outcomes over time. Additional models were estimated to explore whether the intervention effect was mediated by within-person changes in depression. In this sample of 147 adults, we found that participants randomized to escitalopram had significantly larger reductions on both pain severity (b = À14.34, t = À2.66, P < .01) and pain interference (b = À1.20, t = À2.23, P < .05) between baseline and follow-up. After adjusting for within-subject changes in depression, the estimated effects of escitalopram on pain severity and pain interference were virtually identical to the unadjusted effects. This study of opioid-dependent patients with depressive symptoms found that treatment with escitalopram was associated with clinically meaningful reductions in pain severity and pain interference during the first 3 months of therapy. Ó
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Introduction
Pain is common in opioid-dependent patients. Among methadone-treated patients, estimates of chronic pain prevalence range 37-61% [3,14,21]. Several hypothetical pathways may lead to the coexistence of pain and opioid dependence, including depression [2], comorbidities such as HIV [10] or hepatitis C virus [24] , and opioid-induced hyperalgesia [8] . Management of pain in opioiddependent patients is a clinical challenge given concerns for opioid abuse and misuse among individuals with prior substance use disorders [20] . Yet unresolved pain may be a risk factor for relapse among patients whose pain is not fully treated [15] . Some small studies have suggested that buprenorphine/naloxone may be associated with improved pain in opioid-dependent patients with chronic pain [5, 16] . However, a study of opioid-dependent patients who were treated with methadone did not find overall changes in pain level at 1 year [13] . Alternative, nonopioid pharmacologic therapies are needed to address pain in opioid-dependent populations.
Antidepressants may constitute an appealing option for treating pain in opioid-dependent patients because of the frequent coexistence of depression in this population [22] . Systematic reviews and clinical guidelines support the use of antidepressants as pharmacotherapy for chronic pain conditions such as low back pain [7] , fibromyalgia [27] , and neuropathy [23] , with the bulk of research to date being focused on use of tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors. The use of selective serotonin reuptake inhibitors (SSRIs) for chronic pain conditions has been less well studied. Escitalopram belongs to a class of newer SSRIs. It is the S-enantiomer of the SSRI citalopram that has been shown to be responsible for the drug's pharmacologic effect. Two small studies have reported escitalopram to be effective in treating pain in the setting of polyneuropathy [19] and low back pain [17] . No studies have evaluated the effects of escitalopram on pain in opioid-dependent populations.
